Veradermics (MANE) Change in Accured Expenses (2025 - 2026)
Veradermics (MANE) posted Change in Accured Expenses of -$1.4 million for Q1 2026, down 59.28% on a QoQ basis from -$862000.0 in Q1 2025, and down 59.28% year-over-year from -$3.4 million in Q1 2025.
Veradermics (MANE) Change in Accured Expenses (2025 - 2026) Analysis & Trends
Veradermics' Change in Accured Expenses history runs 2 years deep, the most recent figure standing at -$1.4 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Veradermics | 2.61 Bn | 2.61 Bn | - | -1.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.37 Mn |
| Mar 31, 2026 | -1.37 Mn |
| Mar 31, 2025 | -862,000.00 |
| Mar 31, 2025 | -862,000.00 |